, 2002
Dr.
Salt Lake City, UT
Re: (DOB: ;)
Dear Dr. :
On x/x/2002 we performed a DXA bone
density test on your patient X. A Lunar Prodigy DXA scanner was used to
evaluate hip and lumbar regions in the AP projection. The interpretation of the scan is enclosed. The
results show OSTEOPOROSIS of the lumbar spine and OSTEOPENIA (low bone density)
of the hips. No previous scans have
been done. If you have any questions
concerning the scan and results, please don’t hesitate to contact me.
Our
center’s interest is focused on diagnosis, research, and education. It is our philosophy to have the patient’s
personal physician prescribe and coordinate all treatment for osteoporosis. It is recommended that Mr. X have a repeat scan in approximately
two years to assess the response to any medical interventions that might be
recommended.
Sincerely,
John G. Skedros, M.D.
Clinical
Densitometrist
This
test was done to evaluate the bone density in X with the following
indication(s): Advanced age; Corticosteroid use (ICD-9 V58.69); Insulin-dependent diabetes (ICD-9 250.0); Hypogonadism (ICD-9 257.2); Excessive alcohol consumption
Additional
Patient History and Risk Factor Summary*
Caucasian
or Asian race; Loss of more than 1.5 inches in height; History of: Inadequate
exercise, Fracture as an adult, Fracture in a parent or sibling, Depression,
Insulin-dependent diabetes (ICD-9 250.0), Excessive alcohol consumption; Use of
: Tobacco, Caffeinated beverages, Diuretics
*This
information was obtained from our standard survey, which includes many, but not
all, risk factors for osteoporosis or osteoporotic fracture.
Patient’s Name: X () Test
date: x/x/2002
INTERPRETATION
OF THE CURRENT BONE DENSITY TEST
Impression:
OSTEOPOROSIS of the lumbar spine, OSTEOPENIA of the hips.
This is according to the World
Health Organization’s Diagnostic Categories.1
The total lumbar (L2-L4) T-score is substantially lower than the average value found in healthy young adults. The risk for fracture is significantly elevated, and is considered “moderate to high”.
The total T-score of the hip is lower than the average value found in healthy young adults. The risk for fracture is significantly elevated, and is considered “low”. 2
Limitations of study: The scans used appear to be of good technical quality, yielding
reliable results for interpretation.
On this current exam this patient’s bone density is:
|
Compared to: Young normals Same age T-score1 Percent Z-score1 Percent |
|
AP L Spine (L2-L4) -2. % -1. % Hip (total, right & left) -2. % -2. % Forearm NA NA NA NA |
NOTE: The areas of higher fracture risk show the
following T-scores: L2 is –2. ;
Average femoral neck is –2. ;
Average Ward’s triangle is –2. .
1. Definitions:
· T-scores represent standard deviations from the mean of young normal adult women.
· Osteoporosis is a T-score at or below –2.5.
(Some authorities now set the T-score at or below –2.0.)
· Osteopenia is a T-score between –1.0 and –2.5.
· Normal bone mass is a T-score at or above –1.0.
· The Z-score is corrected for persons of the same age.
In postmenopausal females, treatment should be considered for a T-score that is at or below +1.0.
2. The individual fracture risk is based on femoral neck data in De Laet et al.
(1998, J. Bone and Mineral Research, Vol. 13(10):1587-1593).
Additional
note: There is current debate
about how effective antiresorptive drugs are in reducing the incidence of
fractures by increasing bone mineral density.
Recent investigators compiled data from clinical trials of
antiresorptive agents and plotted the relative risk of vertebral fractures
against the average change in BMD for each trial. A conceptual model based on these data showed that treatments
that increase spine BMD by 8% would reduce risk by 54%; most of the total
effect of treatment was explained by the 8% increase in BMD (41% risk
reduction). The small but significant
reductions in risk that were not explained by measurable changes in BMD might
be related to publication bias, measurement errors, or limitations in current
BMD technology (Wasnich and Miller, 2000. J. Clinical Endocrinology &
Metab., 85:231-236.).